Insider Buying: Profound Medical Corp. (TSE:PRN) Senior Officer Purchases C$141,996.45 in Stock

Profound Medical Corp. (TSE:PRN) Senior Officer Thomas Michael Tamberrino acquired 13,333 shares of Profound Medical stock in a transaction on Tuesday, December 10th. The shares were bought at an average cost of C$10.65 per share, for a total transaction of C$141,996.45.

Profound Medical Price Performance

Shares of TSE PRN opened at C$10.56 on Friday. The company has a 50 day simple moving average of C$10.81 and a two-hundred day simple moving average of C$11.60. Profound Medical Corp. has a fifty-two week low of C$9.55 and a fifty-two week high of C$15.75. The company has a market capitalization of C$258.51 million, a price-to-earnings ratio of -6.36 and a beta of 0.81. The company has a debt-to-equity ratio of 16.95, a quick ratio of 14.98 and a current ratio of 8.61.

Analyst Ratings Changes

Separately, Raymond James raised Profound Medical to a “strong-buy” rating in a research report on Saturday, November 9th.

About Profound Medical

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.